Jean-Patrice Baillargeon

List of Publications by Year
in descending order

74 papers	3,731 citations	172443 29 h-index	128286 60 g-index
77 all docs	77 docs citations	77 times ranked	3737 citing authors

#	Article	IF	Citations
1	Protocol of the Fit-For-Fertility study: a multicentre randomised controlled trial assessing a lifestyle programme targeting women with obesity and infertility. BMJ Open, 2022, 12, e061554.	1.9	1
2	Profile of Daughters and Sisters of Women with Polycystic Ovary Syndrome: The Role of Probandâ€™s Glucose Tolerance. Journal of Clinical Endocrinology and Metabolism, 2021, , .	3.6	4
3	DNA methylation at LRP1 gene locus mediates the association between maternal total cholesterol changes in pregnancy and cord blood leptin levels. Journal of Developmental Origins of Health and Disease, 2020, 11, 369-378.	1.4	8
4	Impact of an educational intervention combining clinical obesity preceptorship with electronic networking tools on primary care professionals: a prospective study. BMC Medical Education, 2020, 20, 361.	2.4	4
5	Polycystic Ovary Syndrome and Metabolic Syndrome. Contemporary Endocrinology, 2020, , 255-274.	0.1	0
6	Interplay between intracellular loop 1 and helix VIII of the angiotensin II type 2 receptor controls its activation. Biochemical Pharmacology, 2019, 168, 330-338.	4.4	9
7	Self-Monitoring of Blood Glucose: A Complementary Method Beyond the Oral Glucose Tolerance Test to Identify Hyperglycemia During Pregnancy. Canadian Journal of Diabetes, 2019, 43, 627-635.	0.8	14
8	Male partners of subfertile couples in which the spouse is obese display adverse weight and lifestyle associated with reduced sperm quality. Obesity Research and Clinical Practice, 2019, 13, 226-232.	1.8	9
9	Role of Lipotoxicity and Contribution of the Renin-Angiotensin System in the Development of Polycystic Ovary Syndrome. International Journal of Endocrinology, 2018, 2018, 1-13.	1.5	10
10	Optimizing reproductive health in women with obesity and infertility. Cmaj, 2018, 190, E742-E745.	2.0	17
11	Physical activity assessment and counseling in Quebec family medicine groups. Canadian Family Physician, 2018, 64, e234-e241.	0.4	7
12	Alanine Aminotransferase Is a Marker of Lipotoxicity Consequences and Hyperandrogenemia in Women with Polycystic Ovary Syndrome. Metabolic Syndrome and Related Disorders, 2017, 15, 145-152.	1.3	6
13	Evolution of metabolic alterations 5ÂYears after early puberty in a cohort of girls predisposed to polycystic ovary syndrome. Reproductive Biology and Endocrinology, 2017, 15, 56.	3.3	6
14	PPARGC1Î± gene DNA methylation variations in human placenta mediate the link between maternal hyperglycemia and leptin levels in newborns. Clinical Epigenetics, 2016, 8, 72.	4.1	66
15	CSII. Journal of Diabetes Science and Technology, 2016, 10, 989-990.	2.2	6
16	Regulation of blood flow in adipose tissue: involvement of the cholinergic system. American Journal of Physiology - Endocrinology and Metabolism, 2015, 309, E55-E62.	3.5	1
17	The Obesity-Fertility Protocol: a randomized controlled trial assessing clinical outcomes and costs of a transferable interdisciplinary lifestyle intervention, before and during pregnancy, in obese infertile women. BMC Obesity, 2015, 2, 47.	3.1	15
18	Regional Brain Glucose Hypometabolism in Young Women with Polycystic Ovary Syndrome: Possible Link to Mild Insulin Resistance. PLoS ONE, 2015, 10, e0144116.	2.5	31

#	Article	IF	Citations
19	Effect of Sex and Impaired Glucose Tolerance on Organ-Specific Dietary Fatty Acid Metabolism in Humans. Diabetes, 2015, 64, 2432-2441.	0.6	22
20	Experimental dog model for assessment of fasting and postprandial fatty acid metabolism: pitfalls and feasibility. Laboratory Animals, 2015, 49, 228-240.	1.0	6
21	LRP1B, BRD2 and CACNA1D: new candidate genes in fetal metabolic programming of newborns exposed to maternal hyperglycemia. Epigenomics, 2015, 7, 1111-1122.	2.1	24
22	PCOS in Adolescence and Type 2 Diabetes. Current Diabetes Reports, 2015, 15, 564.	4.2	29
23	Effects of Lifestyle Interventions That Include a Physical Activity Component in Class II and III Obese Individuals: A Systematic Review and Meta-Analysis. PLoS ONE, 2015, 10, e0119017.	2.5	98
24	Impact of an integrated obesity management system on patientâ€™s care - research protocol. BMC Obesity, 2014, 1, 19.	3.1	11
25	Improved cardiac function and dietary fatty acid metabolism after modest weight loss in subjects with impaired glucose tolerance. American Journal of Physiology - Endocrinology and Metabolism, 2014, 306, E1388-E1396.	3.5	24
26	Angiotensin II Type 2 Receptor Stimulation Improves Fatty Acid Ovarian Uptake and Hyperandrogenemia in an Obese Rat Model of Polycystic Ovary Syndrome. Endocrinology, 2014, 155, 3684-3693.	2.8	17
27	Hyperinsulinemia Alters Myoinositol to d-chiroinositol Ratio in the Follicular Fluid of Patients With PCOS. Reproductive Sciences, 2014, 21, 854-858.	2.5	85
28	Insulin Resistance and Lipotoxicity in PCOS: Causes and Consequences. , 2014, , 95-115.		2
29	Angiotensin II type 2 receptor promotes adipocyte differentiation and restores adipocyte size in high-fat/high-fructose diet-induced insulin resistance in rats. American Journal of Physiology - Endocrinology and Metabolism, 2013, 304, E197-E210.	3.5	50
30	Adaptations of placental and cord bloodABCA1ÂDNA methylation profile to maternal metabolic status. Epigenetics, 2013, 8, 1289-1302.	2.7	86
31	Gestational diabetes mellitus epigenetically affects genes predominantly involved in metabolic diseases. Epigenetics, 2013, 8, 935-943.	2.7	217
32	Reference ranges for total and calculated free and bioavailable testosterone in a young healthy women population with normal menstrual cycles or using oral contraception. Clinical Biochemistry, 2012, 45, 148-150.	1.9	13
33	Adipose tissue insulin resistance in peripubertal girls with first-degree family history of polycystic ovary syndrome. Fertility and Sterility, 2012, 98, 1627-1634.	1.0	31
34	Saturated fatty acid exposure induces androgen overproduction in bovine adrenal cells. Steroids, 2012, 77, 347-353.	1.8	24
35	Altered glucose disposition and insulin sensitivity in peri-pubertal first-degree relatives of women with polycystic ovary syndrome. International Journal of Pediatric Endocrinology (Springer), 2012, 2012, 14.	1.6	13
36	AT2 Receptor Agonists: Exploiting the Beneficial Arm of Ang II Signaling. Current Hypertension Reviews, 2012, 8, 47-59.	0.9	14

#	Article	IF	Citations
37	Total and highâ€“molecular weight adiponectin in women with the polycystic ovary syndrome. Metabolism: Clinical and Experimental, 2011, 60, 366-372.	3.4	30
38	Intergenerational Cycle of Obesity and Diabetes: How Can We Reduce the Burdens of These Conditions on the Health of Future Generations?. Experimental Diabetes Research, 2011, 2011, 1-19.	3.8	43
39	Uncoupling Between Insulin and Release of a<scp>d</scp>-Chiro-Inositolâ€“Containing Inositolphosphoglycan Mediator of Insulin Action in Obese Women With Polycystic Ovary Syndrome. Metabolic Syndrome and Related Disorders, 2010, 8, 127-136.	1.3	62
40	Comparison of Foot-to-Foot and Hand-to-Foot Bioelectrical Impedance Methods in a Population with a Wide Range of Body Mass Indices. Metabolic Syndrome and Related Disorders, 2010, 8, 437-441.	1.3	22
41	Current procedures for managing polycystic ovary syndrome. Expert Review of Obstetrics and Gynecology, 2010, 5, 77-91.	0.4	4
42	Brick by brick: metformin for gestational diabetes mellitus?. Expert Review of Endocrinology and Metabolism, 2010, 5, 353-357.	2.4	0
43	Insulin and hyperandrogenism in women with polycystic ovary syndrome. Journal of Steroid Biochemistry and Molecular Biology, 2010, 122, 42-52.	2.5	229
44	Clinically significant and sustained weight loss is achievable in obese women with polycystic ovary syndrome followed in a regular medical practice. Fertility and Sterility, 2010, 94, 2665-2669.	1.0	7
45	Effectiveness of a Multidisciplinary Program for Management of Obesity: The UnitÃ© dâ€™Enseignement, de Traitement et de Recherche sur lâ€™ObÃ©sitÃ© (UETRO) Database Study. Metabolic Syndrome and Related Disorders, 2009, 7, 297-304.	1.3	13
46	Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Fertility and Sterility, 2009, 91, 1750-1754.	1.0	136
47	Hyperinsulinemia is closely related to low urinary clearance of d-chiro-inositol in men with a wide range of insulin sensitivity. Metabolism: Clinical and Experimental, 2009, 58, 62-68.	3.4	12
48	Medical Treatment. , 2009, , 209-232.		2
49	Insulin-stimulated release of d-chiro-inositolâ€“containing inositolphosphoglycan mediator correlates with insulin sensitivity in women with polycystic ovary syndrome. Metabolism: Clinical and Experimental, 2008, 57, 1390-1397.	3.4	109
50	Reply: Correlates between hyperinsulinism and hyperandrogenemia?. Fertility and Sterility, 2008, 89, 1034.	1.0	2
51	Basic Infertility Including Polycystic Ovary Syndrome. Medical Clinics of North America, 2008, 92, 1163-1192.	2.5	115
52	Greek hyperinsulinemic women, with or without polycystic ovary syndrome, display altered inositols metabolism. Human Reproduction, 2008, 23, 1439-1446.	0.9	67
53	Suitability of recommended limits for fasting glucose tests in women with polycystic ovary syndrome. Cmaj, 2007, 176, 933-938.	2.0	28
54	Ovulation induction in polycystic ovary syndromeâ€”how do metformin and clomifene citrate compare?. Nature Clinical Practice Endocrinology and Metabolism, 2007, 3, 512-513.	2.8	6

#	Article	IF	Citations
55	Myo-inositol in patients with polycystic ovary syndrome: A novel method for ovulation induction. Gynecological Endocrinology, 2007, 23, 700-703.	1.7	140
56	Role of insulin in the hyperandrogenemia of lean women with polycystic ovary syndrome and normal insulin sensitivity. Fertility and Sterility, 2007, 88, 886-893.	1.0	88
57	Adrenocortical dysregulation as a major player in insulin resistance and onset of obesity. American Journal of Physiology - Endocrinology and Metabolism, 2007, 293, E1465-E1478.	3.5	80
58	Integrated obesity care management system -implementation and research protocol. BMC Health Services Research, 2007, 7, 163.	2.2	12
59	Brothers of women with polycystic ovary syndrome are characterised by impaired glucose tolerance, reduced insulin sensitivity and related metabolic defects. Diabetologia, 2007, 50, 2424-2432.	6.3	61
60	Insulin Action in Polycystic Ovary Syndrome: In Vivo and In Vitro. , 2007, , 43-68.		8
61	Comparing rosiglitazone with ethinylestradiol/cyproterone acetate in the treatment of polycystic ovary syndrome. Expert Review of Obstetrics and Gynecology, 2006, 1, 81-92.	0.4	2
62	Polycystic Ovary Syndrome: A Syndrome of Ovarian Hypersensitivity to Insulin?. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 22-24.	3.6	135
63	Altered D-Chiro-Inositol Urinary Clearance in Women With Polycystic Ovary Syndrome. Diabetes Care, 2006, 29, 300-305.	8.6	140
64	On the suppression of plasma nonesterified fatty acids by insulin during enhanced intravascular lipolysis in humans. American Journal of Physiology - Endocrinology and Metabolism, 2005, 289, E849-E856.	3.5	60
65	Association between the Current Use of Low-Dose Oral Contraceptives and Cardiovascular Arterial Disease: A Meta-Analysis. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 3863-3870.	3.6	258
66	Use of insulin sensitizers in polycystic ovarian syndrome. Current Opinion in Investigational Drugs, 2005, 6, 1012-22.	2.3	20
67	Reduced Serum Glycodelin and Insulin-Like Growth Factor-Binding Protein-1 in Women with Polycystic Ovary Syndrome during First Trimester of Pregnancy. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 833-839.	3.6	82
68	Metformin Therapy Increases Insulin-Stimulated Release ofd-Chiro-Inositol-Containing Inositolphosphoglycan Mediator in Women with Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 242-249.	3.6	76
69	Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertility and Sterility, 2004, 82, 893-902.	1.0	270
70	A Modern Medical Quandary: Polycystic Ovary Syndrome, Insulin Resistance, and Oral Contraceptive Pills. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 1927-1932.	3.6	146
71	Insulin Sensitizers for Polycystic Ovary Syndrome. Clinical Obstetrics and Gynecology, 2003, 46, 325-340.	1.1	114
72	Effects of D-Chiro-Inositol in Lean Women with the Polycystic Ovary Syndrome. Endocrine Practice, 2002, 8, 417-423.	2.1	150

#	Article	IF	Citations
73	Comparison of metformin and thiazolidinediones in the management of polycystic ovary syndrome. Current Opinion in Endocrinology, Diabetes and Obesity, 2002, 9, 303-311.	0.6	11
74	Combined surgery for coronary artery disease and pheochromocytoma. Canadian Journal of Anaesthesia, 2000, 47, 647-652.	1.6	10